Publication:
Validation of rK39 immunochromatographic test and direct agglutination test for the diagnosis of Mediterranean visceral leishmaniasis in Spain

dc.contributor.authorBangert, Mathieu
dc.contributor.authorFlores-Chavez, Maria
dc.contributor.authorLlanes-Acevedo, Ivonne Pamela
dc.contributor.authorArcones, Carolina
dc.contributor.authorChicharro, Carmen
dc.contributor.authorGarcia, Emilia
dc.contributor.authorOrtega, Sheila
dc.contributor.authorNieto Martinez, Francisco Javier
dc.contributor.authorCruz, Israel
dc.contributor.funderInstituto de Salud Carlos III
dc.date.accessioned2018-12-19T12:06:42Z
dc.date.available2018-12-19T12:06:42Z
dc.date.issued2018-03-01
dc.description.abstractBACKGROUND: Visceral leishmaniasis (VL), the most severe form of leishmaniasis, is endemic in Europe with Mediterranean countries reporting endemic status alongside a worrying northward spread. Serological diagnosis, including immunochromatographic test based on the recombinant antigen rK39 (rK39-ICT) and a direct agglutination test (DAT) based on the whole parasite antigen, have been validated in regions with high VL burden, such as eastern Africa and the Indian subcontinent. To date, no studies using a large set of patients have performed an assessment of both methods within Europe. METHODOLOGY/PRINCIPAL FINDINGS: We selected a range of clinical serum samples from patients with confirmed VL (including HIV co-infection), Chagas disease, malaria, other parasitic infections and negative samples (n = 743; years 2009-2015) to test the performance of rK39-ICT rapid test (Kalazar Detect Rapid Test; InBios International, Inc., USA) and DAT (ITM-DAT/VLG; Institute of Tropical Medicine Antwerp, Belgium). An in-house immunofluorescence antibody test (IFAT), was included for comparison. Estimated sensitivities for rK39-ICT and DAT in HIV-negative VL patients were 83.1% [75.1-91.2] and 84.2% [76.3-92.1], respectively. Sensitivity was reduced to 67.3% [52.7-82.0] for rK39 and increased to 91.3% [82.1-100.0] for DAT in HIV/VL co-infected patients. The in-house IFAT was more sensitive in HIV-negative VL patients, 84.2% [76.3-92.1] than in HIV/VL patients, 79.4% [73.3-96.2]. DAT gave 32 false positives in sera from HIV-negative VL suspects, compared to 0 and 2 for rK39 and IFAT, respectively, but correctly detected more HIV/VL patients (42/46) than rK39 (31/46) and IFAT (39/46). CONCLUSIONS/SIGNIFICANCE: Though rK39-ICT and DAT exhibited acceptable sensitivity and specificity a combination with other tests is required for highly sensitive diagnosis of VL cases in Spain. Important variation in the performance of the tests were seen in patients co-infected with HIV or with other parasitic infections. This study can help inform the choice of serological test to be used when screening or diagnosing VL in a European Mediterranean setting.es_ES
dc.description.peerreviewedes_ES
dc.description.sponsorshipThis work was supported in part by a grant from the Instituto de Salud Carlos III, Acción Estratégica en Salud Intramural—PI 14CIII/00016. IPLA was granted a student fellowship from COLCIENCIAS/COLFUTURO. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.es_ES
dc.format.number3es_ES
dc.format.pagee0006277es_ES
dc.format.volume12es_ES
dc.identifier.citationPLoS Negl Trop Dis. 2018 Mar 1;12(3):e0006277.es_ES
dc.identifier.doi10.1371/journal.pntd.0006277es_ES
dc.identifier.e-issn1935-2735es_ES
dc.identifier.issn1935-2735es_ES
dc.identifier.journalPLoS neglected tropical diseaseses_ES
dc.identifier.pubmedID29494596es_ES
dc.identifier.urihttp://hdl.handle.net/20.500.12105/6907
dc.language.isoenges_ES
dc.publisherPublic Library of Science (PLOS)
dc.relation.projectIDinfo:eu-repo/grantAgreement/ES/PI 14CIII/00016es_ES
dc.relation.publisherversionhttps://doi.org/10.1371/journal.pntd.0006277es_ES
dc.repisalud.centroISCIII::Centro Nacional de Microbiologíaes_ES
dc.repisalud.institucionISCIIIes_ES
dc.rights.accessRightsopen accesses_ES
dc.rights.licenseAtribución 4.0 Internacional*
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/*
dc.subject.meshAdultes_ES
dc.subject.meshAgglutination Testses_ES
dc.subject.meshAntibodies, Protozoanes_ES
dc.subject.meshEndemic Diseaseses_ES
dc.subject.meshFemalees_ES
dc.subject.meshHumanses_ES
dc.subject.meshImmunochromatographyes_ES
dc.subject.meshLeishmania donovanies_ES
dc.subject.meshLeishmaniasis, Viscerales_ES
dc.subject.meshMalees_ES
dc.subject.meshMiddle Agedes_ES
dc.subject.meshPredictive Value of Testses_ES
dc.subject.meshReagent Kits, Diagnostices_ES
dc.titleValidation of rK39 immunochromatographic test and direct agglutination test for the diagnosis of Mediterranean visceral leishmaniasis in Spaines_ES
dc.typeresearch articlees_ES
dc.type.hasVersionVoRes_ES
dspace.entity.typePublication
relation.isAuthorOfPublication458de0b0-d37a-43f1-9049-2af6b69d8f66
relation.isAuthorOfPublicationf7f5ae06-0e03-4f0c-9ec3-b1afd845f525
relation.isAuthorOfPublication9a854aba-a42f-4418-ad59-fb37d799be86
relation.isAuthorOfPublication9ecf7149-0dd1-4072-98fa-17ccdebd450d
relation.isAuthorOfPublication6f88e6f5-6782-4691-8e3a-775581a76358
relation.isAuthorOfPublication7179a4c2-22f1-4de8-8ba0-21abf935bf93
relation.isAuthorOfPublication89c4f5ba-d2da-4007-9e68-74a48b9a16bc
relation.isAuthorOfPublicationb3dc07dc-ad41-46f7-b8a2-9446c6cab831
relation.isAuthorOfPublication4ca3b46e-2faa-4a7d-a134-d198c24d7475
relation.isAuthorOfPublication.latestForDiscovery458de0b0-d37a-43f1-9049-2af6b69d8f66
relation.isFunderOfPublication7d739953-4b68-4675-b5bb-387a9ab74b66
relation.isFunderOfPublication.latestForDiscovery7d739953-4b68-4675-b5bb-387a9ab74b66
relation.isPublisherOfPublicationa2759e3d-0d58-4e8a-9fcd-c6130ee333d1
relation.isPublisherOfPublication.latestForDiscoverya2759e3d-0d58-4e8a-9fcd-c6130ee333d1

Files

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
ValidationOfRK39Immunochromatographic_2018.pdf
Size:
1.31 MB
Format:
Adobe Portable Document Format
Description: